MOH lists abrocitinib on the medical assistance fund

The drug is used to treat atopic dermatitis.

The Ministry of Health (MOH) will list abrocitinib on its Medication Assistance Fund (MAF) on 1 March 2024.

Pfizer's abrocitinib is an oral tablet used to treat moderate-to-severe atopic dermatitis (AD). Eligible patients can now access alternative treatment options from public healthcare institutions.

Abrocitinib has been studied in the JADE clinical program, which involved over 3,800 adults and adolescents with moderate-to-severe AD.

Patients who received abrocitinib reported rapid relief from chronic itch and significant improvements in skin clearance.

“The subsidization of newer therapeutics will now improve accessibility to treatments for AD patients who rely on alternative treatments to manage their symptoms,” Ursula Soh, founder of Eczema Support Group Singapore (ESGS) said.

Follow the link for more news on

Pfizer

healthcare

The people you want to reach are already in this room.

Every quarter, SBR lands on the desks of the founders, CFOs, and directors running Asia's most consequential companies. Every day, they open our newsletter and read our website. It's a room that took twenty years to build — and it's the one most of our partners are trying to get into.

The good news is that the door is open. We work with companies on thought leadership articles, sponsored content, industry summits across Southeast Asia, regional awards programmes, podcasts, and media placements in print and digital. The shape of the right partnership depends on what you're trying to do, which is why we'd rather start with a conversation than send a rate card.

If you have something this room should know about, tell us. We'll tell you honestly whether we can help, and how.

No rate cards until we understand the brief. It's a better use of everyone's time.

Book a meeting

| Or download the media kit (PDF)

240,000 senior readers quarterly in print Top 1,700 Singapore companies reached

7 markets across Southeast Asia